Provided by Tiger Trade Technology Pte. Ltd.

Solid Biosciences

6.86
+0.34005.21%
Pre-market: 6.51-0.3500-5.10%04:54 EST
Volume:1.97M
Turnover:12.94M
Market Cap:534.46M
PE:-2.77
High:6.99
Open:6.57
Low:5.71
Close:6.52
52wk High:7.37
52wk Low:2.41
Shares:77.91M
Float Shares:37.61M
Volume Ratio:1.49
T/O Rate:5.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4800
EPS(LYR):-3.0550
ROE:-86.83%
ROA:-43.67%
PB:2.45
PE(LYR):-2.25

Loading ...

Solid Biosciences Price Target Maintained With a $16.00/Share by Needham

Dow Jones
·
19 hours ago

BRIEF-Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy

Reuters
·
Yesterday

Solid Biosciences Announces FDA Alignment on Phase 3 Trial Design for SGT-003 in Duchenne Muscular Dystrophy

Reuters
·
Yesterday

Solid Biosciences startet Phase-3-Studie mit SGT-003 gegen Duchenne-Muskeldystrophie

Reuters
·
Yesterday

Solid Biosciences Inc - First Participant Dosing Expected in Q1 2026

THOMSON REUTERS
·
Yesterday

Solid Biosciences Inc - Aligns With FDA on Phase 3 Trial Design

THOMSON REUTERS
·
Yesterday

Solid Biosciences Inc - Sgt-003 Well Tolerated in Phase 1/2 Trial With 36 Dosed as of Feb 9

THOMSON REUTERS
·
Yesterday

Solid Biosciences Inc: Company Plans for Additional Meetings With FDA in 1H 2026

THOMSON REUTERS
·
Yesterday

Solid Biosciences Leadership Quietly Unloads a Wave of Insider Shares

TIPRANKS
·
Feb 07

Solid Biosciences CEO Alexander Cumbo Reports Disposal of Common Shares

Reuters
·
Feb 07

Solid Biosciences CTO Paul Herzich Reports Sale of Common Shares

Reuters
·
Feb 07

Solid Biosciences CEO to Present at Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 06

Solid Biosciences participates in a conference call with Cantor

TIPRANKS
·
Feb 04

Solid Biosciences: Leveraging Next-Generation Gene Therapy in DMD to Support a Buy-Rated Risk-Reward Profile

TIPRANKS
·
Feb 03

Solid Biosciences Price Target Maintained With a $16.00/Share by Needham

Dow Jones
·
Jan 15

Solid Biosciences: Advancing DMD Gene Therapy Toward 2026 Value Inflection With Accelerated Approval Potential

TIPRANKS
·
Jan 15

Solid Biosciences Climbs After Multiple Trial Updates

Dow Jones
·
Jan 15

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

GlobeNewswire
·
Jan 14

BRIEF-Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy

Reuters
·
Jan 13

FDA Grants Orphan Drug Designation to Solid Biosciences' SGT-212 for Friedreich’s Ataxia

Reuters
·
Jan 13